Mather Group LLC. Acquires New Holdings in argenx SE (NASDAQ:ARGX)

Mather Group LLC. acquired a new stake in argenx SE (NASDAQ:ARGX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 99 shares of the company’s stock, valued at approximately $38,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ARGX. Parkside Financial Bank & Trust purchased a new position in argenx in the 3rd quarter valued at about $28,000. GAMMA Investing LLC lifted its holdings in argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after purchasing an additional 63 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of argenx during the 4th quarter worth about $38,000. Benjamin F. Edwards & Company Inc. purchased a new position in shares of argenx during the 4th quarter worth about $60,000. Finally, Principal Securities Inc. purchased a new position in shares of argenx during the 4th quarter worth about $99,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of ARGX opened at $440.59 on Tuesday. The business’s fifty day moving average price is $376.64 and its 200 day moving average price is $386.49. argenx SE has a 12-month low of $327.73 and a 12-month high of $550.76. The stock has a market capitalization of $26.18 billion, a PE ratio of -77.84 and a beta of 0.65.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million for the quarter, compared to the consensus estimate of $404.03 million. argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. During the same quarter last year, the business earned ($0.52) earnings per share. As a group, research analysts anticipate that argenx SE will post -2.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ARGX. Wedbush reiterated an “outperform” rating and set a $521.00 price objective on shares of argenx in a report on Thursday, April 18th. Morgan Stanley cut their price target on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a report on Tuesday, May 28th. Scotiabank raised their price target on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a report on Tuesday, March 26th. HC Wainwright restated a “buy” rating and issued a $448.00 price target on shares of argenx in a report on Monday. Finally, JPMorgan Chase & Co. lowered their price objective on shares of argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, May 13th. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $523.42.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.